Extended Table 4.
Anti-drug antibodies levels to 2141-V11
| ID | Cancer type | DL | # cycles | Cycle | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | ||||
| 01 | TNBC | 1 | 2 | - | - | ||||||||||||||||
| 02 | TNBC | 1 | 5 | - | - | - | - | - | |||||||||||||
| 05 | TNBC | 1 | 2 | - | - | ||||||||||||||||
|
| |||||||||||||||||||||
| 06 | Mel | 2 | 13 | NA | - | - | 20 | 160 | 2560 | 2560 | 2560 | 2560 | 2560 | 1280 | 1280 | 1280 | 1280 | 1280 | 640 | 320 | 160 |
| 07 | TNBC | 2 | 4 | - | - | - | - | ||||||||||||||
| 08 | TNBC | 2 | 5 | - | - | - | - | - | |||||||||||||
|
| |||||||||||||||||||||
| 09 | Mel | 3 | 16 | - | 160 | 320 | 640 | 1280 | 1280 | 1280 | 1280 | 1280 | 640 | 640 | 640 | 320 | 320 | 160 | 160 | ||
| 10 | ccRCC | 3 | 9 | - | - | - | - | 20 | 20 | 20 | - | - | |||||||||
| 12 | ccRCC | 3 | 3 | - | - | ||||||||||||||||
|
| |||||||||||||||||||||
| 14 | ER+BC | 3 | 3 | - | - | - | - | 20 | 40 | 20 | 20 | 20 | 20 | 20 | |||||||
| 11 | TNBC | 3 | 2 | - | - | ||||||||||||||||
| 15 | Muc Mel | 3 | 4 | - | - | - | - | ||||||||||||||
Blood was drawn before each cycle, immediately prior to administration of 2141-V11.
Anti-drug antibody levels are based on the sample dilution factor.
Mel: Melanoma; TNBC: Triple negative breast cancer, ER+BC: Estrogen receptor positive breast cancer, ccRCC: clear cell renal cell carcinoma, Muc Mel: mucosal melanoma